GlaxoSmithKline is expanding its restructuring programme in order to generate an additional, annual pre-tax savings of £500 million by 2012. Half of the savings will come from R&D where it intends to stop discovery research in depression and pain.
GlaxoSmithKline is expanding its restructuring programme in order to generate an additional, annual pre-tax savings of £500 million by 2012. Half of the savings will come from R&D where it intends to stop discovery research in depression and pain.